TARDBP and proteostasis deficiencies: The biosensordesign and counter-screening strategy allows us to identify compoundsthat bias the TDP-43 ensemble toward nuclear NTD-dependent interactions.The identification of an NTD-dependent small molecule capable of rescuingTDP-43-induced deficits demonstrates that this platform is a noveland exciting therapeutic discovery platform for FTD, ALS, and otherTDP-43 proteinopathies.